Rare lephants
Screener

20/20 BIOLABS, INC.

AIDX ·Healthcare, Diagnostics & Research, United States
Analysis › Moat Score

Moat Score — 20/20 Biolabs, Inc.

Total Moat Score 7 / 30
Moat Factor Score Analysis
Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. 2 / 5 Owns a CAP-accredited, CLIA-licensed lab and proprietary protein-marker testing methodology, but lacks the extensive clinical validation data and patent estate of larger MCED competitors like Grail.
Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. 2 / 5 A genuine structural cost edge versus premium-priced Galleri (sub-$200 vs. ~$949) driven by a simpler protein-marker approach, though this may reflect narrower test scope rather than pure operating efficiency.
Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. 1 / 5 Competes explicitly on being the low-cost option, meaning its strategy depends on low prices rather than the ability to command premium pricing.
Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. 0 / 5 Diagnostic testing does not benefit from user network effects; more test-takers do not directly make the test more valuable to other customers.
Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. 1 / 5 Some stickiness with CLIAx lab-service clients who integrate their regulatory/testing workflow into 20/20's facility, but individual cancer-screening consumers face minimal switching costs.
Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. 1 / 5 A single CLIA lab serving a still-small customer base offers limited efficient-scale protection against much larger, better-capitalized diagnostics companies entering the same MCED category.